Targeted approaches to induce immune tolerance for Pompe disease therapy
Year: 2016
Type: review
Abstract: Enzyme and gene replacement strategies have developed into viable therapeutic approaches for the treatment of Pompe disease (acid α-glucosidase (GAA) deficiency). Unfortunately, the introduction of GAA and viral vectors encoding the enzyme can lead to detrimental immune responses that attenuate treatment benefits and can impact patient safety. Preclinical and clinical experience in addressing humoral responses toward enzyme and gene therapy for Pompe disease have provided greater understanding of the immunological consequences of the provided therapy. B- and T-cell modulation has been shown to be effective in preventing infusion-associated reactions during enzyme replacement therapy in patients and has shown similar success in the context of gene therapy. Additional techniques to induce humoral tolerance for Pompe disease have been the targeted expression or delivery of GAA to discrete cell types or tissues such as the gut-associated lymphoid tissues, red blood cells, hematopoietic stem cells, and the liver. Research into overcoming preexisting immunity through immunomodulation and gene transfer are becoming increasingly important to achieve long-term efficacy. This review highlights the advances in therapies as well as the improved understanding of the molecular mechanisms involved in the humoral immune response with emphasis on methods employed to overcome responses associated with enzyme and gene therapies for Pompe disease.
DOI: 10.1038/mtm.2015.53
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Keywords: Pompe disease, acid alpha-glucosidase deficiency, immune tolerance, humoral immune response, enzyme replacement therapy, gene therapy, viral vectors, infusion reactions, T cell regulation, targeted gene delivery, hematopoietic stem cells, liver-directed gene transfer, gut-associated lymphoid tissue, pre-existing immunity
Open Access status: gold
Estimated APC paid: $3,900
Awards: Gene Therapy for Lung and Cardiovascular Disease, Together: Transforming and Translating Discovery to Improve Health, Affordable Oral Delivery of Human Therapeutic Proteins Bioencapsulated in Plant Cells, UF Clinical and Translational Science Award, G5500374692, G815619472, Control of Breathing and Pompe Disease, G9000111155, G9000279110, Fuller T32 renewal
OpenAlex ID: W2282860096
